The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society–USA Panel
Abstract
CONTEXT: Guidelines for antiretroviral therapy are important for clinicians worldwide given the complexity of the field and the varied clinical situations in which these agents are used. The International AIDS Society-USA panel has updated its recommendations as warranted by new developments in the field. OBJECTIVE: To provide physicians and other human immunodeficiency virus (HIV) clinicians with current recommendations for the use of antiretroviral therapy in HIV-infected adults in circumstances for which there is relatively unrestricted access to drugs and monitoring tools. The recommendations are centered on 4 key issues: when to start antiretroviral therapy; what to start; when to change; and what to change. Antiretroviral therapy in special circumstances is also described. DATA SOURCES AND STUDY SELECTION: A 16-member noncompensated panel was appointed, based on expertise in HIV research and patient care internationally. Data published or presented at selected scientific conferences from mid 2004 through May 2006 were identified and reviewed by all members of the panel. DATA EXTRACTION AND SYNTHESIS: Data that might change previous guidelines were identified and reviewed. New guidelines were drafted by a writing committee and reviewed by the entire panel. CONCLUSIONS: Antiretroviral therapy in adults continues to evolve rapidly, making delivery of state-of-the-art care challenging. Initiation of therapy continues to be recommended in all symptomatic persons and in asymptomatic persons after the CD4 cell count falls below 350/microL and before it declines to 200/microL. A nonnucleoside reverse transcriptase inhibitor or a protease inhibitor boosted with low-dose ritonavir each combined with 2 nucleoside (or nucleotide) reverse transcriptase inhibitors is recommended with choice being based on the individual patient profile. Therapy should be changed when toxicity or intolerance mandate it or when treatment failure is documented. The virologic target for patients with treatment failure is now a plasma HIV-1 RNA level below 50 copies/mL. Adherence to antiretroviral therapy in the short-term and the long-term is crucial for treatment success and must be continually reinforced.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., & Markowitz, M. (1995) · Nature · doi:10.1038/373123a0 · Cited by 4,267
Viral dynamics in human immunodeficiency virus type 1 infection
Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., et al. (1995) · Nature · doi:10.1038/373117a0 · Cited by 3,260
Self-citationBrenchley, J. M., Schacker, T. W., Ruff, L. E., Price, D. A., Taylor, J. H., Beilman, G. J., Nguyen, P. L., Khoruts, A., Larson, M., Haase, A. T., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040874 · Cited by 1,832
Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men--New York City and California.
Friedman‐Kien, A. E., Laubenstein, L. J., Marmor, M. F., Hymes, K. B., Green, J., Ragaz, A., Gottleib, J., Muggia, F. M., Demopoulos, R. I., & Weintraub, M. R. (1981) · MMWR Morbidity and Mortality Weekly Report · Cited by 1,739
Diagnosis, management, and treatment of hepatitis C†
Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B. (2004) · Hepatology · doi:10.1002/hep.20119 · Cited by 1,709
UPDATE ON DRUG RESISTANCE MUTATIONS IN HIV-1
&NA; (2001) · Infectious Diseases in Clinical Practice · doi:10.1097/00019048-200106000-00020 · Cited by 1,660
Egger, M., May, M., Chêne, G., Phillips, A. N., Ledergerber, B., Dabis, F., Costagliola, D., Monforte, A. D., de Wolf, F., Reiss, P., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09411-4 · Cited by 1,525
Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07873-x · Cited by 1,380
Gallant, J. E. (2004) · JAMA · doi:10.1001/jama.292.2.191 · Cited by 1,341
Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection
Mattapallil, J. J., Douek, D. C., Hill, B., Nishimura, Y., Martin, M., & Roederer, M. (2005) · Nature · doi:10.1038/nature03501 · Cited by 1,278
Mehandru, S., Poles, M. A., Tenner-Racz, K., Horowitz, A., Hurley, A., Hogan, C., Boden, D., Racz, P., & Markowitz, M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041196 · Cited by 1,146
Staszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D. F., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women
Mosca, L., Appel, L. J., Benjamin, E. J., Berra, K., Chandra-Strobos, N., Fabunmi, R. P., Grady, D., Haan, C. K., Hayes, S. N., Judelson, D. R., et al. (2004) · Circulation · doi:10.1161/01.cir.0000114834.85476.81 · Cited by 917
Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America
Lalezari, J. P., Henry, K., O'Hearn, M., Montaner, J. S. G., Piliero, P. J., Trottier, B., Walmsley, S., Cohen, C., Kuritzkes, D. R., Eron, J. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035026 · Cited by 914
Self-citationTenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
Gallant, J. E., DeJesus, E., Arribas, J. R., Pozniak, A. L., Gazzard, B., Campo, R. E., Lu, B., McColl, D., Chuck, S., Enejosa, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051871 · Cited by 880
Self-citationAberg, J. A., Kaplan, J. E., Libman, H., Emmanuel, P., Anderson, J. R., Stone, V. E., Oleske, J. M., Currier, J. S., & Gallant, J. E. (2009) · Clinical Infectious Diseases · doi:10.1086/605292 · Cited by 837
Treatment for Adult HIV Infection: 2004 Recommendations of the International AIDS Society-USA Panel
Yeni, P. G., Hammer, S. M., Hirsch, M. S., Saag, M. S., Schechter, M., Carpenter, C. C. J., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Jacobsen, D. M., et al. (2004) · JAMA · doi:10.1001/jama.292.2.251 · Cited by 737
Self-citationEfficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
Lazzarin, A., Clotet, B., Cooper, D., Reynes, J., Arastéh, K., Nelson, M., Katlama, C., Stellbrink, H.-J., Delfraissy, J.-F., Lange, J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035211 · Cited by 656
Deeks, S. G., Wrin, T., Liegler, T., Hoh, R., Hayden, M., Barbour, J. D., Hellmann, N. S., Petropoulos, C. J., McCune, J. M., Hellerstein, M. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102153440702 · Cited by 653
Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection
Walmsley, S., Bernstein, B., King, M., Arribas, J., Beall, G., Ruane, P., Johnson, M., Johnson, D., Lalonde, R., Japour, A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012354 · Cited by 647
Haas, D. W., Ribaudo, H. J., Kim, R. B., Tierney, C., Wilkinson, G. R., Gulick, R. M., Clifford, D. B., Hulgan, T., Marzolini, C., & Acosta, E. P. (2004) · PubMed · Cited by 627
Gupta, S. K., Eustace, J. A., Winston, J. A., Boydstun, I. I., Ahuja, T. S., Rodriguez, R. A., Tashima, K. T., Roland, M., Franceschini, N., Palella, F. J., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/430257 · Cited by 581
HIV disease: fallout from a mucosal catastrophe?
Brenchley, J. M., Price, D. A., & Douek, D. C. (2006) · Nature Immunology · doi:10.1038/ni1316 · Cited by 579
Hirsch, M. S., Conway, B., D'Aquila, R. T., Johnson, V. A., Brun-Vézinet, F., Clotet, B., Demeter, L. M., Hammer, S. M., Jacobsen, D. M., Kuritzkes, D. R., et al. (1998) · JAMA · doi:10.1001/jama.279.24.1984 · Cited by 563
Self-citationBadri, M., Wilson, D., & Wood, R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08904-3 · Cited by 556
Sex Differences in Pharmacokinetics and Pharmacodynamics
Gandhi, M., Aweeka, F., Greenblatt, R. M., & Blaschke, T. F. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121453 · Cited by 542
Carpenter, C. C. J. (1996) · JAMA · doi:10.1001/jama.276.2.146 · Cited by 541
Self-citationEron, J. J., Benoit, S. L., Jemsek, J., MacArthur, R. D., Santana, J., Quinn, J. B., Kuritzkes, D. R., Fallon, M. A., & Rubin, M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512213332502 · Cited by 531
HIV viral load markers in clinical practice
Saag, M. S., Holodniy, M., Kuritzkes, D. R., O'Brien, W. A., Coombs, R., Poscher, M. E., Jacobsen, D. M., Shaw, G. M., Richman, D. D., & Volberding, P. A. (1996) · Nature Medicine · doi:10.1038/nm0696-625 · Cited by 524
Self-citationGulick, R. M., Ribaudo, H. J., Shikuma, C. M., Lustgarten, S., Squires, K. E., Meyer, W. A., Acosta, E. P., Schackman, B. R., Pilcher, C. D., Murphy, R. L., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031772 · Cited by 522
Hirsch, M. S., Brun‐Vezinet, F., Clotet, B., Conway, B., Kuritzkes, D. R., D’Aquila, R. T., Demeter, L. M., Hammer, S. M., Johnson, V. A., Loveday, C., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/375597 · Cited by 514
Self-citationMartin, A. M., Nolan, D., Gaudieri, S., Almeida, C. A., Nolan, R., James, I., Carvalho, F., Phillips, E., Christiansen, F. T., Purcell, A. W., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307067101 · Cited by 452
Intermittent HIV-1 Viremia (Blips) and Drug Resistance in Patients Receiving HAART
Nettles, R. E. (2005) · JAMA · doi:10.1001/jama.293.7.817 · Cited by 395
Rockstroh, J. K., Mocroft, A., Soriano, V., Tural, C., Losso, M. H., Horban, A., Kirk, O., Phillips, A., Ledergerber, B., Lundgren, J., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/432762 · Cited by 383
Schambelan, M., Benson, C. A., Carr, A., Currier, J. S., Dubé, M. P., Gerber, J. G., Grinspoon, S. K., Grunfeld, C., Kotler, D. P., Mulligan, K., et al. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200211010-00001 · Cited by 379
Self-citationParadoxical reactions during tuberculosis treatment in patients with and without HIV co-infection
Breen, R. A. M. (2004) · Thorax · doi:10.1136/thx.2003.019224 · Cited by 367
Descamps, D. (2000) · JAMA · doi:10.1001/jama.283.2.205 · Cited by 367
Prevalence and Predictive Value of Intermittent Viremia With Combination HIV Therapy
Havlir, D. V. (2001) · JAMA · doi:10.1001/jama.286.2.171 · Cited by 358
Bartlett, J. A. (2004) · Infectious Diseases in Clinical Practice · Cited by 352
Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection
Robbins, G. K., De Gruttola, V., Shafer, R. W., Smeaton, L. M., Snyder, S. W., Pettinelli, C., Dubé, M. P., Fischl, M. A., Pollard, R. B., Delapenha, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030264 · Cited by 351
Self-citationGallant, J. E., Parish, M. A., Keruly, J. C., & Moore, R. D. (2005) · Clinical Infectious Diseases · doi:10.1086/428840 · Cited by 302
Havlir, D. V. (2000) · JAMA · doi:10.1001/jama.283.2.229 · Cited by 297
Martin, A., Smith, D. E., Carr, A., Ringland, C., Amin, J., Emery, S., Hoy, J., Workman, C., Doong, N., Freund, J., et al. (2004) · AIDS · doi:10.1097/00002030-200404300-00011 · Cited by 297
Rauch, A., Nolan, D., Martin, A., McKinnon, E., Almeida, C., & Mallal, S. (2006) · Clinical Infectious Diseases · doi:10.1086/504874 · Cited by 296
Martínez, E., Arnaiz, J. A., Podzamczer, D., Dalmau, D., Ribera, E., Domingo, P., Knobel, H., Riera, M., Pedrol, E., Force, L., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021589 · Cited by 291
Self-citationvan Leth, F., Phanuphak, P., Stroes, E., Gazzard, B., Cahn, P., Raffi, F., Wood, R., Bloch, M., Katlama, C., Kastelein, J. J. P., et al. (2004) · PLoS Medicine · doi:10.1371/journal.pmed.0010019 · Cited by 276
Self-citationStructured Treatment Interruption in Patients with Multidrug-Resistant Human Immunodeficiency Virus
Lawrence, J., Mayers, D. L., Hullsiek, K. H., Collins, G., Abrams, D. I., Reisler, R. B., Crane, L. R., Schmetter, B. S., Dionne, T. J., Saldanha, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035103 · Cited by 268
Viral Dynamics in HIV-1 Infection
Finzi, D., & Siliciano, R. F. (1998) · Cell · doi:10.1016/s0092-8674(00)81427-0 · Cited by 266
Raboud, J. M., Montaner, J. S. G., Conway, B., Rae, S., Reiss, P., Vella, S., Cooper, D., Lange, J., Harris, M., Wainberg, M. A., et al. (1998) · AIDS · doi:10.1097/00002030-199813000-00008 · Cited by 259
Self-citationDore, G. J., Cooper, D. A., Pozniak, A. L., DeJesus, E., Zhong, L., Miller, M. D., Lu, B., Cheng, A. K., & Teams, T. 9. A. 9. S. (2004) · The Journal of Infectious Diseases · doi:10.1086/380398 · Cited by 253
Johnson, M., Grinsztejn, B., Rodriguez, C., Coco, J., DeJesus, E., Lazzarin, A., Lichtenstein, K., Rightmire, A., Sankoh, S., & Wilber, R. (2005) · AIDS · doi:10.1097/01.aids.0000166091.39317.99 · Cited by 248
Severe Hepatotoxicity Associated with Nevirapine Use in HIV‐Infected Subjects
Sanne, I., Mommeja‐Marin, H., Hinkle, J., Bartlett, J. A., Lederman, M. M., Maartens, G., Wakeford, C., Shaw, A., Quinn, J., Gish, R. G., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/428093 · Cited by 242
Marschner, I. C., Collier, A. C., Coombs, R. W., D'Aquila, R. T., DeGruttola, V., Fischl, M. A., Hammer, S. M., Hughes, M. D., Johnson, V. A., Katzenstein, D. A., et al. (1998) · The Journal of Infectious Diseases · doi:10.1086/513823 · Cited by 240
Self-citationShafer, R. W., Smeaton, L. M., Robbins, G. K., De Gruttola, V., Snyder, S. W., D'Aquila, R. T., Johnson, V. A., Morse, G. D., Nokta, M. A., Martinez, A. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030265 · Cited by 228
Self-citationRibaudo, H. J., Haas, D. W., Tierney, C., Kim, R. B., Wilkinson, G. R., Gulick, R. M., Clifford, D. B., Marzolini, C., Fletcher, C. V., Tashima, K. T., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/499364 · Cited by 221
Gulick, R. M. (2006) · JAMA · doi:10.1001/jama.296.7.769 · Cited by 219
Burger, D., Van Der Heiden, I., La Porte, C., Van Der Ende, M., Groeneveld, P., Richter, C., Koopmans, P., Kroon, F., Sprenger, H., Lindemans, J., et al. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02536.x · Cited by 209
Lichtenstein, K. A., Delaney, K. M., Armon, C., Ward, D. J., Moorman, A. C., Wood, K. C., & Holmberg, S. D. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200301010-00007 · Cited by 203
Gilbert Syndrome and the Development of Antiretroviral Therapy–Associated Hyperbilirubinemia
Rotger, M., Taffé, P., Bleiber, G., Günthard, H. F., Furrer, H., Vernazza, P., Drechsler, H., Bernasconi, E., Rickenbach, M., Telenti, A., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/466531 · Cited by 194
Sex Differences in Longitudinal Human Immunodeficiency Virus Type 1 RNA Levels among Seroconverters
Sterling, T. R., Lyles, C. M., Vlahov, D., Astemborski, J., Margolick, J. B., & Quinn, T. C. (1999) · The Journal of Infectious Diseases · doi:10.1086/314967 · Cited by 180
Myelomeningocele in a child with intrauterine exposure to efavirenz
Fundaro, C., Genovese, O., Rendeli, C., Tamburrini, E., & Salvaggio, E. (2002) · AIDS · doi:10.1097/00002030-200201250-00025 · Cited by 160
Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients
Benhamou, Y., Fleury, H., Trimoulet, P., Pellegrin, I., Urbinelli, R., Katlama, C., Rozenbaum, W., Le Teuff, G., Trylesinski, A., & Piketty, C. (2006) · Hepatology · doi:10.1002/hep.21055 · Cited by 159
Nelson, M. R., Arastéh, K., Clotet, B., Cooper, D. A., Henry, K., Katlama, C., Lalezari, J. P., Lazzarin, A., Montaner, J. S. G., O’Hearn, M., et al. (2005) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000185314.56556.c3 · Cited by 152
Self-citationArribas, J. R., Pulido, F., Delgado, R. B., Lorenzo, A., Miralles, P., Arranz, A., González‐García, J., Cepeda, C., Hervás, R., Paño, J. R., et al. (2005) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000180077.59159.f4 · Cited by 151
Deeks, S. G., Hoh, R., Neilands, T. B., Liegler, T. J., Aweeka, F. T., Petropoulos, C. J., Grant, R. M., & Martin, J. N. (2005) · The Journal of Infectious Diseases · doi:10.1086/496892 · Cited by 151
Anastos, K., Schneider, M. F., Gange, S. J., MINKOFF, H. L., Greenblatt, R. M., Feldman, J. G., Levine, A. M., Delapenha, R., & Cohen, M. H. (2005) · PubMed · Cited by 145
Antiretroviral nucleoside and nucleotide analogues and mitochondria
Cossarizza, A., & Moyle, G. J. (2004) · AIDS · doi:10.1097/00002030-200401230-00002 · Cited by 144
Periconceptional Exposure to Efavirenz and Neural Tube Defects
Santis, M. D., Carducci, B., Santis, L. D., Cavaliere, A. F., & Straface, G. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.3.355 · Cited by 140
Podzamczer, D., Ferrer, E., Consiglio, E., Gatell, J. M., Pérez, P., Pérez, J. L., Luna, E., González, A., Pedrol, E., Lozano, L., et al. (2002) · Antiviral Therapy · doi:10.1177/135965350200700202 · Cited by 137
Self-citationDART Virology Group and Trial Team (2006) · AIDS · doi:10.1097/01.aids.0000233572.59522.45 · Cited by 129
Duration of Highly Active Antiretroviral Therapy Regimens
Chen, R. Y., Westfall, A. O., Mugavero, M. J., Cloud, G. A., Raper, J. L., Chatham, A., Acosta, E. P., Taylor, K. H., Carter, J., & Saag, M. S. (2003) · Clinical Infectious Diseases · doi:10.1086/377271 · Cited by 100
Self-citationCurrier, J. S., Spino, C., Grimes, J. M., Wofsy, C. B., Katzenstein, D. A., Hughes, M. D., Hammer, S. M., & Cotton, D. J. (2000) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200008010-00003 · Cited by 99
Self-citationSterling, T. R., Chaisson, R. E., Keruly, J. C., & Moore, R. D. (2003) · The Journal of Infectious Diseases · doi:10.1086/379741 · Cited by 92
Schluger, N. W., Perez, D., & Liu, Y. M. (2002) · CHEST Journal · doi:10.1378/chest.122.2.597 · Cited by 91
Swindells, S. (2006) · JAMA · doi:10.1001/jama.296.7.806 · Cited by 84
Management of Newly Diagnosed HIV Infection
Hammer, S. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp051203 · Cited by 83
Self-citationGerstoft, J., Kirk, O., Obel, N., Pedersen, C., Mathiesen, L., Nielsen, H. I., Katzenstein, T. L., & Lundgren, J. D. (2003) · AIDS · doi:10.1097/00002030-200309260-00005 · Cited by 79
Kumar, P. N., Rodriguez‐French, A., Thompson, M., Tashima, K. T., Averitt, D., Wannamaker, P. G., Williams, V. C., Shaefer, M. S., Pakes, G. E., Pappa, K. A., et al. (2006) · HIV Medicine · doi:10.1111/j.1468-1293.2006.00346.x · Cited by 74
Self-citationNicastri, E., Chiesi, A., Angeletti, C., et al. (2005) · Journal of Medical Virology · doi:10.1002/jmv.20352 · Cited by 72
Sex Differences in Antiretroviral Therapy-Associated Intolerance and Adverse Events
Clark, R. A. (2005) · Drug Safety · doi:10.2165/00002018-200528120-00003 · Cited by 71
Muro, E. P., Droste, J. A. H., ter Hofstede, H. J. M., Bosch, M., Dolmans, W. M. V., & Burger, D. M. (2005) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000167154.37357.f9 · Cited by 63
Macías, J., Palomares, J. C., Mira, J. A. L., Torres, M. J., García-García, J. Á., Rodriquez, J. M., Vergera, S., & Pineda, J. A. (2005) · Journal of Infection · doi:10.1016/j.jinf.2004.11.010 · Cited by 58
Early Virological Failure with a Combination of Tenofovir, Didanosine and Efavirenz
Podzamczer, D., Ferrer, E., Gatell, J. M., Niubó, J., Dalmau, D., León, A., Knobel, H., Polo, C., Iniguez, D., & Ruiz, I. C. (2005) · Antiviral Therapy · doi:10.1177/135965350501000117 · Cited by 58
Self-citationMoore, D. M., Hogg, R. S., Chan, K., TYNDALL, M. W., Yip, B., & Montaner, J. S. (2006) · AIDS · doi:10.1097/01.aids.0000196180.11293.9a · Cited by 56
Self-citationPredicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA
Rizzardi, G. P., de Boer, R. J., Hoover, S. B., Tambussi, G., Chapuis, A. G., Halkic, N., Bart, P., Miller, V., Staszewski, S., Notermans, D. W., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9079 · Cited by 50
Atherogenic lipid profile and cardiovascular risk factors in HIV-infected patients (Nétar Study)
Santos, J. C. D. C., Palacios, R., González, M., Ruiz, J., & Márquez, M. (2005) · International Journal of STD & AIDS · doi:10.1258/095646205774357398 · Cited by 44
Moyle, G. J., Higgs, C. J., Teague, A., Mandalia, S., Nelson, M. R., Johnson, M. A., Fisher, M., & Gazzard, B. (2006) · Antiviral Therapy · doi:10.1177/135965350601100106 · Cited by 43
Self-citationRaboud, J., Rae, S. L., Hogg, R. S., Yip, B., Sherlock, C. H., Harrigan, P. R., O'Shaughnessy, M. V., & Montaner, J. S. G. (1999) · The Journal of Infectious Diseases · doi:10.1086/314998 · Cited by 42
Self-citationLo, J. C.-M., Kazemi, M., Hsue, P. Y., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/496981 · Cited by 38
The Nonnucleoside Reverse Transcriptase Inhibitors Efavirenz and Nevirapine in the Treatment of HIV
Michael, S. (2005) · HIV Clinical Trials · doi:10.1310/4kc0-56tm-vlbf-78bn · Cited by 15
Cited by
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
Self-citationTenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
Marcellin, P., Heathcote, E. J., Buti, M., Gane, E., de Man, R. A., Krastev, Z., Germanidis, G., Lee, S. S., Flisiak, R., Kaita, K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802878 · Cited by 1,181
Combinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070
Evaluation of networks of randomized trials
Salanti, G., Higgins, J. P., Ades, A., & Ioannidis, J. P. (2008) · Statistical Methods in Medical Research · doi:10.1177/0962280207080643 · Cited by 1,078
Metadata
- Authors
- Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M. A., Carpenter, C. C. J., Fischl, M. A., Gazzard, B. G., Gatell, J. M., Hirsch, M. S., Katzenstein, D. A., Richman, D. D., Vella, S., Yeni, P. G., & Volberding, P. A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2006-08-16
- Volume
- 296
- Issue
- 7
- Pages
- 827
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2122280827
- Cited by
- 1,033
- References
- 94
- FWCI
- 123.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.